Products

 

NUTRACEUTICAL – COLON CANCER

Enhancing treatment of Gold Standard therapy in colorectal cancer.

Forchronic has developed a validated nutritional supplement in the context of precision nutrition, formulated from rosemary extract, with supercritical extraction, which has immunomodulatory and anti-inflammatory activity, and which inhibits the synthesis of DNA and lipid metabolism at the molecular level and, consequently, inhibits cell proliferation as well as the migration of tumor cells (metastasis) in colon cancer.

The formula of this compound contains a lipid carrier of high bioactivity, which allows to approach therapeutic strategies for cancer through similar products in the food field and therefore, considered nutritional supplements and not drugs. This lipid carrier increases the bioavailability of the active ingredients, improving the stability of the product during digestion and its bioavailability.

 

The formulation strategy for bioactive carrier lipids is exclusive of Forchronic, which bases it on the development of new precision nutrition products and specific use for health.

 

Current phase: in clinical trials.

Development of the Bioactive Suplement

Preclinical Phase

 

Clinical Trials

Lab studies

Assays in animals

Clinical trial in healthy volunteers

Pilot study in phase 0/I

Clinical trial in phase II/III

Identification of the compound
Development of
the compound
Inhibition of molecular pathways associated with tumor growth
Potentiation of chemotherapy (fluoropyridines)
Made in 60
healthy volunteers
Absence of toxicity and potentiation of the immune system
Made in 11 patients
for 2 weeks
Verification of tolerability, absence of toxicity and enhancement of the immune system
Multicenter trial in 150 colon cancer patients receiving chemotherapy (5-Fu)
Under review by the
ClinicaResearch Ethics
Committee 
This new nutritional supplement of Forchronic showed satisfactory results in vitro and in preclinical (animal tests), as well as in a clinical trial in healthy volunteers, where it was demonstrated that there is no sign of toxicity and its association with precision nutrition was shown, identifying the genes and metabolic pathways involved.

In the current phase of clinical trials in patients with colorectal cancer the first positive results have already been obtained.

The preventive, antitumor and immune potentiating properties shown in the trial in healthy volunteers have also been observed in sick patients.

 

 

La fórmula de este compuesto contiene un portador lipídico de elevada bioactividad, que permite abordar estrategias terapéuticas para el cáncer mediante productos similares en el ámbito alimentario y por tanto, considerados complementos nutricionales y no fármacos. Este carrier lipídico aumenta la biodisponibilidad de los principios activos, mejorando la estabilidad del producto durante la digestión y la bioaccesibilidad del mismo.

La estrategia de formulación sobre lípidos portadores bioactivos es exclusiva de Forchronic que basa en ella el desarrollo de nuevos productos de nutrición de precisión y de uso específicos para la salud.

Current status

in clinical trials

 

Development in Bioactive Suplement

Lab studies

Identification of the compound
Development of
the compound

Preclinical Phase

 

Assays in animals

Inhibition of molecular pathways associated with tumor growth
Potentiation of chemotherapy (fluoropyridines)

Clinical Trials 

Clinical trial in healthy volunteers

Made in 60
healthy volunteers
Absence of toxicity and potentiation of the immune system

Pilot study in phase 0/I

Made in

11 patients

for 2 weeks

Verification of tolerability, absence of toxicity and enhancement of the immune system

Clinical trial in phase II/III

Multicenter trial in 150 colon cancer patients receiving chemotherapy (5-Fu)
Under review by the Clinica
l Research Ethics Committee

 

Investigación Clínica
This new nutritional supplement of Forchronic showed satisfactory results in vitro and in preclinical (animal tests), as well as in a clinical trial in healthy volunteers, where it was demonstrated that there is no sign of toxicity and its association with precision nutrition was shown, identifying the genes and metabolic pathways involved.

In the current phase of clinical trials in patients with colorectal cancer the first positive results have already been obtained.

The preventive, antitumor and immune potentiating properties shown in the trial in healthy volunteers have also been observed in sick patients.

 

NUTRACEUTICAL – BREAST CANCER

Development of the nutritional supplement based on rosemary extract with therapeutic activity in breast cancer.

Current phase: start phase II / III of clinical trials in 100 patients with breast cancer at the beginning of 2020.

Development in Bioactive Suplement

In vitro assays / preclinical phase

Clinical Trial with Healthy volunteers

Clinical Trial in Patients

NUTRACEUTICAL – OTHER TUMORS

Applicability of the nutraceutical product based on rosemary extract and carried in the lipid vehicle of high bioactivity in other types of tumors, such as lung cancer.

Current phase: start phase II / III of clinical trials in 50 patients with lung cancer at the beginning of 2020.

NUTRACEUTICAL – AUTOIMMUNE DISEASES:

Study and development of the nutritional compound based on rosemary carried in the patented lipid carrier for the treatment of autoimmune diseases such as Rheumatoid Arthritis, Type I Diabetes, Psoriasis, Celiac Disease and Multiple Sclerosis.

Current phase: clinical trials in healthy volunteers.

NEWS NUTRACEUTICAL PRODUCTS

Extracts of yarrow and calendula for pancreatic cancer, obesity, metabolic syndrome and metabolic diseases.

Current phase: preclinical phase. Forecast to clinical trial in human volunteers for extract of yarrow.

Phone

(+34) 91 395 40 80

(+34) 91 395 40 81

Address

C/ Agustín de Betancourt, nº 21

7th floor, office 716
28003 MADRID

Email

administracion@canaanrd.com

Office Hours

Monday – Friday

8:15 – 16:45